Results 271 to 280 of about 58,972 (283)

Clinical outcomes in sarcoidosis after cessation of infliximab treatment

Respirology, 2009
Marc A Judson
exaly  

Infliximab

Reactions Weekly, 2020
openaire   +1 more source

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Lancet, The, 2002
J Braun, W Golder, H Sorensen
exaly  

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology, 2015
Peter Bossuyt, Christine Breynaert, Tom Cattaert   +2 more
exaly  

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center

Arthritis and Rheumatism, 2005
Sandeep K Agarwal, Lori B Chibnik, Jonathan S Coblyn   +2 more
exaly  

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

Clinical Gastroenterology and Hepatology, 2016
Johannan F Brandse, Ron A Mathot, Jeroen M Jansen   +2 more
exaly  

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis

British Journal of Clinical Pharmacology, 2012
David Ternant, Denis Mulleman, Emilie Ducourau   +2 more
exaly  

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Byong Duk Ye, M F Osipenko, Adi Lahat
exaly  

Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD

Inflammatory Bowel Diseases, 2015
Emil Chuang, Sharat Singh, Mitchell Paul D   +2 more
exaly  

Infliximab

Reactions Weekly
openaire   +2 more sources